MCI-225 hydrochloride hydrate | CAS#476148-82-0 | CAS#99487-25-9 | 5-HT3/5-HT

MedKoo Cat#: 526996 | Name: MCI-225 hydrochloride hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MCI-225, also known as AA-10021; AA-10025; AA-10026; DDP-225, is a norepinephrine reuptake/5-HT3/5-HT reuptake inhibitor potentially for the treatment of irritable. MCI-225 enhances attentional eye tracking in midpontine pretrigeminal preparation. MCI-225 could be effective in the treatment of senile dementia of the Alzheimer type, which is accompanied with both deficit in the BF-cortex cholinergic neuron and cerebral glucose hypometabolism.

Chemical Structure

MCI-225 hydrochloride hydrate

CAS#476148-82-0 (HCl hydrate)

Theoretical Analysis

MedKoo Cat#: 526996

Name: MCI-225 hydrochloride hydrate

CAS#: 476148-82-0 (HCl hydrate)

Chemical Formula: C17H20ClFN4OS

Exact Mass:

Molecular Weight: 382.88

Elemental Analysis: C, 53.33; H, 5.27; Cl, 9.26; F, 4.96; N, 14.63; O, 4.18; S, 8.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

476148-82-0 (HCl hydrate) 135991-48-9(free base) 99487-26-0(HCl)

Synonym

MCI-225 hydrochloride hydrate, MCI225; AA-10021; AA-10025; AA-10026; DDP-225; AA10021; AA10025; AA10026; DDP225.

IUPAC/Chemical Name

Thieno(2,3-d)pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, monohydrochloride, monohydrate

InChi Key

SAURKKOJWIFYSR-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H17FN4S.ClH.H2O/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22;;/h2-5,10,19H,6-9H2,1H3;1H;1H2

SMILES Code

CC1=CC2=C(C3=CC=CC=C3F)N=C(N4CCNCC4)N=C2S1.[H]Cl.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 99487-25-9 (MCI-225 Free) 476148-82-0 (MCI-225 hydrochloride hydrate)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 382.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Eguchi J, Inomata Y, Saito K. The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism. Pharmacol Biochem Behav. 2001 Apr;68(4):677-83. PubMed PMID: 11526964. 2: Ishigooka J. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)]. Nihon Rinsho. 2001 Aug;59(8):1523-9. Review. Japanese. PubMed PMID: 11519152. 3: Wu YL, Yoshida M, Emoto H, Ishii H, Koga K, Tanaka M. Effects of acute and chronic administration of MCI-225, a new selective noradrenaline reuptake inhibitor with 5-HT3 receptor blocking action, on extracellular noradrenaline levels in the hypothalamus of stressed rats. Jpn J Pharmacol. 2000 May;83(1):31-8. PubMed PMID: 10887938. 4: MCI 225. Drugs R D. 1999 Jul;2(1):51-2. PubMed PMID: 10610283. 5: Eguchi J, Inomata Y, Yuasa T, Egawa M, Saito K. Pharmacological profile of the novel antidepressant 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine monohydrate hydrochloride. Arzneimittelforschung. 1997 Dec;47(12):1337-47. PubMed PMID: 9450161. 6: Eguchi J, Saitoh Y, Egawa M, Saito K, Kawamura H. MCI-225, a novel thienopyrimidine analog, enhances attentional eye tracking in midpontine pretrigeminal preparation. Pharmacol Biochem Behav. 1997 Feb;56(2):229-34. PubMed PMID: 9050079. 7: Eguchi J, Iwai K, Yuasa T, Egawa M, Komatsu T, Saito K. Effects of MCI-225 on memory and glucose utilization in basal forebrain-lesioned rats. Pharmacol Biochem Behav. 1995 Aug;51(4):935-9. PubMed PMID: 7675880. 8: Eguchi J, Yuasa T, Egawa M, Tobe A. Effects of a novel compound MCI-225 on impaired learning and memory in rats. Pharmacol Biochem Behav. 1994 Jun;48(2):345-9. PubMed PMID: 8090800. 9: Oishi R, Itoh Y, Adachi N, Saeki K. Effect of a new psychoactive compound, MCI-225, on brain monoamine metabolism in rats. Jpn J Pharmacol. 1993 Oct;63(2):261-4. PubMed PMID: 8283838.